Waldencast (WALD) Aktievy
Waldencast plc är verksamt inom skönhets- och hälsobranschen i USA, Kanada, Europa, Mellanöstern, Indien, Australien och Nya Zeeland. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 4/6 |
| Utdelningar | 0/6 |
WALD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Waldencast plc Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$1.66 |
| 52 veckors högsta | US$3.22 |
| 52 veckors lägsta | US$0.72 |
| Beta | 0.093 |
| 1 månads förändring | 26.72% |
| 3 månaders förändring | 40.08% |
| 1 års förändring | -26.22% |
| 3 års förändring | -82.15% |
| 5 års förändring | n/a |
| Förändring sedan börsintroduktionen | -78.47% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jun 15
WALD: Obagi Sale And Injectables Launch Will Support Future Upside
Analysts have lifted their price target on Waldencast stock to $3.00 from $2.50, citing the agreed sale of the Obagi skin care and aesthetics business for up to $460m and the view that current valuation does not fully reflect the strength of Obagi, Milk and the upcoming Saypha injectables launch. Analyst Commentary Bullish analysts see the agreed sale of the Obagi skin care and aesthetics business and the ongoing investment in Saypha injectables as key supports for the recent reset to a $3.00 price target.
Uppdatering av berättelse • Jun 01
WALD: Brand Strength And Injectables Expansion Will Drive Future Repricing Despite Higher Costs
Narrative Update on Waldencast Analysts have lowered their average price targets on Waldencast by about $1 to a range around $2 to $2.50, citing recent EBITDA and sales misses, ongoing costs tied to regulatory and review processes, and what they describe as slower recent growth. At the same time, they continue to point to the perceived strength of the Obagi and Milk brands, as well as potential from the Saypha injectables launch.Recent updates
Uppdatering av berättelse • Jun 15
WALD: Obagi Sale And Injectables Launch Will Support Future Upside
Analysts have lifted their price target on Waldencast stock to $3.00 from $2.50, citing the agreed sale of the Obagi skin care and aesthetics business for up to $460m and the view that current valuation does not fully reflect the strength of Obagi, Milk and the upcoming Saypha injectables launch. Analyst Commentary Bullish analysts see the agreed sale of the Obagi skin care and aesthetics business and the ongoing investment in Saypha injectables as key supports for the recent reset to a $3.00 price target.Uppdatering av berättelse • Jun 01
WALD: Brand Strength And Injectables Expansion Will Drive Future Repricing Despite Higher Costs
Narrative Update on Waldencast Analysts have lowered their average price targets on Waldencast by about $1 to a range around $2 to $2.50, citing recent EBITDA and sales misses, ongoing costs tied to regulatory and review processes, and what they describe as slower recent growth. At the same time, they continue to point to the perceived strength of the Obagi and Milk brands, as well as potential from the Saypha injectables launch.
Uppdatering av berättelse • May 04
WALD: Brand Strength And Injectables Launch Will Support Future Share Rebound
Analysts have trimmed their average price target on Waldencast from about $3.08 to roughly $1.87, reflecting recent EBITDA and sales shortfalls, slower growth and higher costs. At the same time, they point to ongoing brand strength and potential upside from the Saypha injectables launch.Uppdatering av berättelse • Apr 20
WALD: Brand Strength And Injectables Rollout Will Support Future Repricing
Analysts have trimmed their average price target for Waldencast to a range of $2.00 to $2.50, reflecting recent EBITDA and sales shortfalls, higher ongoing review and investigation costs, and more moderate revenue growth assumptions. They continue to highlight the strength of the Obagi and Milk brands, as well as potential upside from the Saypha injectables launch.Uppdatering av berättelse • Apr 05
WALD: Brand Equity And Aesthetics Partnerships Will Support Future Upside
Analysts have trimmed their average price targets for Waldencast to a range of about $2 to $2.50 from prior levels near $3 to $4, citing recent EBITDA and sales misses, ongoing SEC and review related costs, and the view that the brands still have room to grow despite a transition period. Analyst Commentary Recent research updates show that while targets have been reduced, several bullish analysts still view Waldencast as an early stage, brand driven story in a transition phase.Uppdatering av berättelse • Mar 22
WALD: Aesthetics Partnerships And Brand Strength Will Support Future Upside
Analysts have trimmed their average price target on Waldencast to $2.50, down from $4.00, reflecting recent earnings misses, ongoing investment in the Saypha injectables launch, slower-than-expected growth and higher costs tied to regulatory and review processes, even as they continue to highlight the strength of the Obagi and Milk brands. Analyst Commentary Bullish analysts are cutting their price targets on Waldencast, but several still point to what they see as underappreciated assets and future product catalysts.Uppdatering av berättelse • Mar 07
WALD: Jefferies Buy Rating And Aesthetics Partnerships Will Support $4 Upside
Analysts have raised their blended price target for Waldencast to $4.00, citing updated assumptions that include a lower discount rate, an adjusted profit margin outlook, and a higher future P/E multiple, as well as support from recent Street research. Analyst Commentary Street research around Waldencast has tilted constructive, with bullish analysts pointing to a clearer earnings path and a more supportive valuation framework behind the updated US$4.00 blended price target.Uppdatering av berättelse • Feb 21
WALD: Future Margin Recovery And Distribution Gains Will Support Share Rebound
Analysts have held Waldencast's price target at $3.00, with the latest updates reflecting lower assumed profit margins and a higher future P/E multiple, while incorporating mixed recent research that includes a Buy initiation and a prior downgrade after "disappointing" Q2 results and a reduced FY25 outlook. Analyst Commentary Recent commentary around Waldencast reflects a split view, with some focusing on long term brand potential and others zeroing in on execution hiccups and trimmed outlooks.Uppdatering av berättelse • Feb 06
WALD: Future Retail Distribution Gains Will Support Recovery After Earnings Setbacks
Narrative Update on Waldencast The analyst price target for Waldencast has been revised slightly lower to about $3.08 from about $3.20, as analysts balance a higher discount rate and a lower assumed future P/E with generally supportive views following the recent Jefferies initiation, along with concerns highlighted after Telsey's reaction to "disappointing" Q2 results and the reduced FY25 outlook. Analyst Commentary Recent research on Waldencast reflects a mix of optimism around the long term brand opportunity and caution around execution and near term earnings delivery.Uppdatering av berättelse • Jan 23
WALD: Expanded Beauty Distribution Will Support $4 Upside After Mixed Research
Analysts have trimmed their price target on Waldencast to $4.00, reflecting a slightly higher discount rate and modest adjustments to growth and P/E assumptions following mixed recent research, including a downgrade after "disappointing" Q2 results and an assumed rating elsewhere. Analyst Commentary Recent research on Waldencast sends a mixed signal, with one firm trimming its stance after Q2 and another assuming coverage with a more constructive view.Analysartikel • Jan 10
Waldencast plc's (NASDAQ:WALD) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors
Waldencast plc ( NASDAQ:WALD ) shareholders won't be pleased to see that the share price has had a very rough month...Uppdatering av berättelse • Jan 07
WALD: Expanded Beauty Distribution Will Support Recovery After Recent Guidance Reset
Analysts now hold Waldencast's fair value steady at about US$4.00 per share, with a US$3.00 price target that reflects caution after what they describe as disappointing Q2 results, reduced FY25 guidance, and sales pressure at the Milk brand despite broader distribution gains. Analyst Commentary Even with the recent downgrade and cautious stance on near term execution, some commentary still points to potential upside drivers that investors are watching closely.Uppdatering av berättelse • Dec 14
WALD: Expanded Beauty Distribution Will Drive Rebound After Recent Earnings Reset
Analysts have trimmed their price target on Waldencast to about $4 from roughly $5, citing weaker than expected Q2 results, a lowered FY25 outlook, and slower growth at key brand Milk despite new distribution gains. Analyst Commentary Bullish analysts acknowledge that recent results and guidance have pressured near term expectations, but they continue to see upside potential for Waldencast as execution improves and the growth algorithm normalizes.Uppdatering av berättelse • Nov 28
WALD: Future Retail Partnerships Will Drive Recovery After Recent Setbacks
Analysts have revised Waldencast's price target downward from $3.50 to $3.20, citing weaker than expected quarterly results and ongoing challenges impacting sales growth and profitability. Analyst Commentary Bullish Takeaways Despite near-term headwinds, Waldencast continues to increase its distribution footprint.Analysartikel • Nov 26
Waldencast (NASDAQ:WALD) Is Carrying A Fair Bit Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Nov 26
Revenues Tell The Story For Waldencast plc (NASDAQ:WALD) As Its Stock Soars 33%
Waldencast plc ( NASDAQ:WALD ) shares have continued their recent momentum with a 33% gain in the last month alone. Not...Seeking Alpha • Sep 23
Waldencast: Fairly Valued With Ulta Lift Already Reflected, Saypha Deal Adds Optionality
Summary Waldencast faces ongoing challenges with slowing revenue growth, heavy debt, and profitability concerns despite recent margin expansion. WALD's acquisition of Novaestiq aims to double its addressable market by entering the U.S. dermal filler space under the Obagi brand, with risk-mitigating deal terms. Recent trading updates show Milk Makeup's U.S. growth via Ulta and Amazon, while Obagi excels internationally, but overall FY 2025 guidance has been lowered. Despite a potential 20% upside to the $2.50–2.70 range, I maintain a 'Hold' rating as structural issues and dilution risks persist. Read the full article on Seeking AlphaAnalysartikel • Aug 21
Waldencast plc (NASDAQ:WALD) Stocks Pounded By 26% But Not Lagging Industry On Growth Or Pricing
NasdaqCM:WALD 1 Year Share Price vs Fair Value Explore Waldencast's Fair Values from the Community and select yours The...Uppdatering av berättelse • Aug 21
Expansion Into Ulta Beauty Stores Will Boost Future Success
The Analyst Price Target for Waldencast was reduced to $3.50 from $3.98, reflecting concerns about softer international demand, operational disruptions, strategic uncertainty, and delayed reporting, despite some positive momentum at core brands. Analyst Commentary Moderated annual outlook due to softening international consumption and out-of-stock issues at Waldencast brands.Analysartikel • May 14
We Think Waldencast (NASDAQ:WALD) Has A Fair Chunk Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysartikel • Apr 09
It's Down 29% But Waldencast plc (NASDAQ:WALD) Could Be Riskier Than It Looks
Waldencast plc ( NASDAQ:WALD ) shareholders that were waiting for something to happen have been dealt a blow with a 29...
Ny berättelse • Mar 30
Expansion Into Ulta Beauty Stores Will Boost Future Success
Strong growth in Milk Makeup and Obagi Medical, with store expansion and innovation driving increased future revenue and market share.Analysartikel • Aug 13
Waldencast plc (NASDAQ:WALD) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, Waldencast plc ( NASDAQ:WALD ) shares are down a considerable 26% in the last...Seeking Alpha • Jun 28
Waldencast Plc: Investors Continue To Demand More Growth
Summary Waldencast plc provides 'Milk Makeup' & 'Obagi' brands in beauty & wellness industry. Q1 2024 saw 21% revenue growth, improved profitability trends, and increased adjusted EBITDA for Waldencast. Fiscal 2024 guidance includes expectations of continued growth through e-commerce, international sales, and brand partnerships. Read the full article on Seeking AlphaAnalysartikel • Jun 19
We Think Waldencast (NASDAQ:WALD) Has A Fair Chunk Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • May 11
Waldencast plc (NASDAQ:WALD) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
To the annoyance of some shareholders, Waldencast plc ( NASDAQ:WALD ) shares are down a considerable 29% in the last...Analysartikel • Apr 07
Waldencast plc's (NASDAQ:WALD) Intrinsic Value Is Potentially 55% Above Its Share Price
Key Insights Waldencast's estimated fair value is US$14.29 based on 2 Stage Free Cash Flow to Equity Waldencast's...Analysartikel • Dec 14
Is Waldencast plc (NASDAQ:WALD) Trading At A 42% Discount?
How far off is Waldencast plc ( NASDAQ:WALD ) from its intrinsic value? Using the most recent financial data, we'll...Aktieägarnas avkastning
| WALD | US Personal Products | US Marknad | |
|---|---|---|---|
| 7D | -10.8% | -1.1% | 1.7% |
| 1Y | -26.2% | -16.3% | 25.1% |
Avkastning vs industri: WALD presterade sämre än US Personal Products branschen som gav -16.3 % under det senaste året.
Avkastning vs Marknaden: WALD presterade sämre än US marknaden som gav 25.1 % under det senaste året.
Prisvolatilitet
| WALD volatility | |
|---|---|
| WALD Average Weekly Movement | 22.2% |
| Personal Products Industry Average Movement | 8.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: WALD s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: WALD s veckovolatilitet har ökat från 15% till 22% under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2020 | 367 | Michel Brousset | www.waldencast.com |
Waldencast plc är verksamt inom skönhets- och hälsobranschen i USA, Kanada, Europa, Mellanöstern, Indien, Australien och Nya Zeeland. Bolaget bedriver verksamhet genom två segment, Obagi Medical och Milk Makeup. Bolaget erbjuder hudvårdsprodukter för att minimera tecken på hudåldrande, motverka mörka fläckar, hyperpigmentering, fina linjer och rynkor samt skydda och förbättra hudton och hudstruktur, kosmetika och andra skönhetsprodukter.
Waldencast plc Sammanfattning av grunderna
| WALD grundläggande statistik | |
|---|---|
| Börsvärde | US$212.81m |
| Vinst(TTM) | -US$229.75m |
| Intäkter(TTM) | US$272.07m |
0.7x
P/S-förhållande-0.9x
P/E-förhållandeÄr WALD övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| WALD resultaträkning (TTM) | |
|---|---|
| Intäkter | US$272.07m |
| Kostnad för intäkter | US$89.05m |
| Bruttovinst | US$183.02m |
| Övriga kostnader | US$412.77m |
| Intäkter | -US$229.75m |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -1.94 |
| Bruttomarginal | 67.27% |
| Nettovinstmarginal | -84.44% |
| Skuld/egenkapitalförhållande | 27.3% |
Hur har WALD utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/19 15:36 |
| Aktiekurs vid dagens slut | 2026/06/18 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Waldencast plc bevakas av 5 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Susan Anderson | Canaccord Genuity |
| Olivia Tong Cheang | Raymond James & Associates |